Tsunemoto H, Yoo S Y
National Institute of Radiological Sciences, Chiba-shi, Japan.
Bull Cancer Radiother. 1996;83 Suppl:93s-100s. doi: 10.1016/0924-4212(96)84891-2.
In Asian countries, fast neutron therapy was first introduced at the National Institute of Radiological Sciences (NIRS), and followed by the Institute of Medical Science (IMS), Tokyo University, and Korea Cancer Center Hospital (KCCH). At NIRS, 2,129 patients were treated with d(30 MeV)+Be neutrons between 1975 and 1994. There were 274 patients referred for the treatment with P(50.5 MeV)+Be neutrons at KCCH during the period of 1986 through 1992. Unfortunately, fast neutron therapy performed at IMS was discontinued in 1991, where 458 patients had been treated with d(14 MeV)+Be neutrons since 1976. At NIRS, a vertical beam with multileaf collimator system was used for treatment of patients referred. The results showed that local control rates were 79% (19/24), 53% (14/26), and 89.3% (50/56) for carcinoma of the salivary gland, osteogenic sarcoma and carcinoma of the prostate, while complications for those were found to be 8.8, 8.3 and 17.8%, respectively. In the treatment of carcinoma of the lung, results were better for patients with adenocarcinoma than those with squamous cell carcinoma. Of 32 patients suffering from Pancoast tumor, 14 achieved local control, whereas 2 of 32 patients developed complications. On the other hand, salvage surgery was required in the treatment of malignant melanoma. In the treatment of malignant glioma, dose localization has to be improved in the target area to confirm local control. Experiences performed at KCCH have shown that, of 53 patients suffering from unresectable primary or recurrent rectal carcinomas, 28 achieved local control. It was concluded from the experiences with fast neutrons in Asian countries that adenocarcinomas as well as slowly growing tumors are indications for fast neutrons and that dose localization has to be improved in order to advance high LET radiation therapy. Clinical trials with 70 MeV protons started at NIRS in 1979, where the aim of study has been focused on treatment of choroidal melanoma, whereas, at Tsukuba University, 250 MeV protons have been used in the treatment of tumors deeply seated. Based on experiences of fast neutrons and protons, clinical trials with heavy ions initiated at NIRS in October 1994. Clinical studies with high LET radiations will be performed by using heavy ions in order to pursue indications of particle radiation therapy.
在亚洲国家,国立放射科学研究所(NIRS)率先引入快中子疗法,随后东京大学医学科学研究所(IMS)和韩国癌症中心医院(KCCH)也相继开展。在NIRS,1975年至1994年间有2129例患者接受了d(30兆电子伏特)+铍中子治疗。1986年至1992年期间,KCCH有274例患者被转诊接受P(50.5兆电子伏特)+铍中子治疗。不幸的是,IMS的快中子疗法于1991年停止,自1976年以来已有458例患者接受了d(14兆电子伏特)+铍中子治疗。在NIRS,使用带有多叶准直器系统的垂直束对转诊患者进行治疗。结果显示,唾液腺癌、骨肉瘤和前列腺癌的局部控制率分别为79%(19/24)、53%(14/26)和89.3%(50/56),而这些疾病的并发症发生率分别为8.8%、8.3%和17.8%。在肺癌治疗中,腺癌患者的治疗效果优于鳞状细胞癌患者。32例患潘科斯特瘤的患者中,14例实现了局部控制,而32例患者中有2例出现并发症。另一方面,恶性黑色素瘤治疗需要进行挽救性手术。在恶性胶质瘤治疗中,必须改善靶区的剂量定位以确认局部控制效果。KCCH的经验表明,53例无法切除的原发性或复发性直肠癌患者中,28例实现了局部控制。从亚洲国家快中子治疗的经验得出结论,腺癌以及生长缓慢的肿瘤是快中子治疗的适应证,并且必须改善剂量定位以推进高传能线密度放射治疗。1979年NIRS开始了70兆电子伏特质子的临床试验,其研究重点一直是脉络膜黑色素瘤治疗,而筑波大学则使用250兆电子伏特质子治疗深部肿瘤。基于快中子和质子的治疗经验,1994年10月NIRS启动了重离子临床试验。将通过使用重离子进行高传能线密度辐射的临床研究,以探索粒子放射治疗的适应证。